Leukemia, Acute Lymphoblastic, Leukemia, Biphenotypic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Lymphoblastic Lymphoma, Precursor B-Cell Lymphoblastic Leukemia
Conditions
Brief summary
The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.
Detailed description
1. Acquisition of informed concent form 2. Data acquisition from medical record including * demographic / disease-associated factors * details of treatment, and its results * complications during treatment * genetic data * survival outcome (upto 10 years) 3. Accumulation of data for 30 years 4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)
Interventions
OTHERDiagnosed as ALL
All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma) * 15 years of age and over * All patients who give written consent according to guidelines at Asan Medical Center committee on human research
Exclusion criteria
* Patients who refuse to give consent to registering
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | 10 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | 10 years | Definition of events will be as 'relapse', 'death from any cause'. Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia |
| Relapse-free survival | 10 years | Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia |
Countries
South Korea
Outcome results
None listed